PubRank

Bisphosphonates for Prevention of Post-Denosumab Bone Loss

Clinical Trial ID NCT03396315

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT03396315

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008 2.37
2 Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 1998 1.75
3 Bone microarchitecture and stiffness in premenopausal women with idiopathic osteoporosis. J Clin Endocrinol Metab 2009 1.61
4 Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 2011 1.59
5 Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports. Osteoporos Int 2015 1.53
6 Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 2001 1.33
7 Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int 2011 1.26
8 Abnormal bone microarchitecture and evidence of osteoblast dysfunction in premenopausal women with idiopathic osteoporosis. J Clin Endocrinol Metab 2011 1.11
9 Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res 2000 1.05
10 Premenopausal women with idiopathic low-trauma fractures and/or low bone mineral density. Osteoporos Int 2011 1.03
11 Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics. Osteoporos Int 2015 1.02
12 Teriparatide for idiopathic osteoporosis in premenopausal women: a pilot study. J Clin Endocrinol Metab 2013 0.98
13 Increases in bone mineral density after discontinuation of daily human parathyroid hormone and gonadotropin-releasing hormone analog administration in women with endometriosis. J Clin Endocrinol Metab 1999 0.91
14 Severe rebound-associated vertebral fractures after denosumab discontinuation: nine clinical cases report. J Clin Endocrinol Metab 2016 0.90
15 Central QCT reveals lower volumetric BMD and stiffness in premenopausal women with idiopathic osteoporosis, regardless of fracture history. J Clin Endocrinol Metab 2012 0.85
16 Multiple clinical vertebral fractures following denosumab discontinuation. Osteoporos Int 2015 0.83
17 Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases. J Bone Miner Res 2017 0.80
18 Bone Density After Teriparatide Discontinuation in Premenopausal Idiopathic Osteoporosis. J Clin Endocrinol Metab 2015 0.76
19 Bone Loss After Denosumab: Only Partial Protection with Zoledronate. Calcif Tissue Int 2017 0.75
20 Bisphosphonates or denosumab discontinuation and risk of fractures. Maturitas 2017 0.75
21 Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment. Eur J Endocrinol 2017 0.75
Next 100